News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) To Discuss Biomarkers In Fragile X And Autism Trials At The Second Annual Autism Investment Conference



2/24/2014 8:50:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine extended-release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will give a presentation entitled, "The Use of Biomarkers in Fragile X and Autism Clinical Trials," at Autism Speaks' Autism Investment Conference, being held at the Bently Reserve Banking Hall in San Francisco on March 4-5, 2014. The Alcobra presentation is on Tuesday, March 4, during the "Medicines and Therapeutic Devices" session.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Alcobra
 
 
Autism

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES